Abstract:Lidocaine can elicit direct scavenging activity at high concentrations that might be important at or near the site of injection in local anaesthetic use.
“…This observation agrees with another study showing that LID at comparable concentrations decreased ROS generated in neutrophils 64. LID has also been reported to have a direct scavenging effect on peroxynitrite63 and on singlet oxygen 62. Therefore, the protective mechanisms of LID on mitochondrial function could be attributed to either blocking electron flow to down stream complexes (complex III), where greater ROS generation occurs during oxidative stress,14 to scavenging of mitochondrial ROS, or to both mechanisms.…”
Mitochondria are damaged by cardiac ischemia-reperfusion (I/R) injury but can contribute to cardioprotection. We tested if hyperkalemic cardioplegia (CP) and lidocaine (LID) differently modulate mitochondrial (m) bioenergetics and protect hearts against I/R injury. Guinea pig hearts (n=71) were perfused with Krebs Ringer's (KR) solution before perfusion for 1 min just before ischemia with either CP ( ] and superoxide (ROS) were assessed at baseline, during the 1 min perfusion, and continuously during I/R. During the brief perfusion before ischemia, CP and LID decreased ROS and increased NADH without changing m [Ca 2+ ]. Additionally, CP decreased FAD. During ischemia, NADH was higher and ROS was lower after CP and LID, whereas m [Ca 2+ ] was lower only after LID. On reperfusion, NADH and FAD were more normalized, and m [Ca 2+ ] and ROS remained lower after CP and LID. Better functional recovery and smaller infarct size after CP and LID were accompanied by better mitochondrial function. These results suggest that mitochondria may be implicated, directly or indirectly, in protection by CP and LID against I/R injury.
“…This observation agrees with another study showing that LID at comparable concentrations decreased ROS generated in neutrophils 64. LID has also been reported to have a direct scavenging effect on peroxynitrite63 and on singlet oxygen 62. Therefore, the protective mechanisms of LID on mitochondrial function could be attributed to either blocking electron flow to down stream complexes (complex III), where greater ROS generation occurs during oxidative stress,14 to scavenging of mitochondrial ROS, or to both mechanisms.…”
Mitochondria are damaged by cardiac ischemia-reperfusion (I/R) injury but can contribute to cardioprotection. We tested if hyperkalemic cardioplegia (CP) and lidocaine (LID) differently modulate mitochondrial (m) bioenergetics and protect hearts against I/R injury. Guinea pig hearts (n=71) were perfused with Krebs Ringer's (KR) solution before perfusion for 1 min just before ischemia with either CP ( ] and superoxide (ROS) were assessed at baseline, during the 1 min perfusion, and continuously during I/R. During the brief perfusion before ischemia, CP and LID decreased ROS and increased NADH without changing m [Ca 2+ ]. Additionally, CP decreased FAD. During ischemia, NADH was higher and ROS was lower after CP and LID, whereas m [Ca 2+ ] was lower only after LID. On reperfusion, NADH and FAD were more normalized, and m [Ca 2+ ] and ROS remained lower after CP and LID. Better functional recovery and smaller infarct size after CP and LID were accompanied by better mitochondrial function. These results suggest that mitochondria may be implicated, directly or indirectly, in protection by CP and LID against I/R injury.
“…Inflammatory cells produce peroxynitrite by the reaction between nitric oxide and superoxide anion, both of which are present in inflamed tissues. Peroxynitrite is also known to react with lidocaine and bupivacaine [43, 44]. Ueno et al [41] focused on inflammatory peroxynitrite responsible for the local anesthetic failure of inflamed tissues.…”
Section: Change Of Membrane Interactivitymentioning
Despite a long history in medical and dental application, the molecular mechanism and precise site of action are still arguable for local anesthetics. Their effects are considered to be induced by acting on functional proteins, on membrane lipids, or on both. Local anesthetics primarily interact with sodium channels embedded in cell membranes to reduce the excitability of nerve cells and cardiomyocytes or produce a malfunction of the cardiovascular system. However, the membrane protein-interacting theory cannot explain all of the pharmacological and toxicological features of local anesthetics. The administered drug molecules must diffuse through the lipid barriers of nerve sheaths and penetrate into or across the lipid bilayers of cell membranes to reach the acting site on transmembrane proteins. Amphiphilic local anesthetics interact hydrophobically and electrostatically with lipid bilayers and modify their physicochemical property, with the direct inhibition of membrane functions, and with the resultant alteration of the membrane lipid environments surrounding transmembrane proteins and the subsequent protein conformational change, leading to the inhibition of channel functions. We review recent studies on the interaction of local anesthetics with biomembranes consisting of phospholipids and cholesterol. Understanding the membrane interactivity of local anesthetics would provide novel insights into their anesthetic and cardiotoxic effects.
“…[ 49 ] Such a sodium channel blockade also helps preserve myocardial adenosine triphosphate during ischemia and reperfusion due to the suppression of Na + /K + -ATPase activity and mitochondrial calcium loading. [ 45 , 50 ] Furthermore, lidocaine has been reported to reduce myocardial free radical generation [ 51 ] and apoptosis. [ 46 ] Those mechanisms may partly explain the association between intravenous lidocaine and a reduction in the length of hospital and ICU stay in the current meta-analysis.…”
Background:
This study aimed at providing an updated evidence of the association between intraoperative lidocaine and risk of postcardiac surgery cognitive deficit.
Methods:
Randomized clinical trials (RCTs) investigating effects of intravenous lidocaine against cognitive deficit in adults undergoing cardiac surgeries were retrieved from the EMBASE, MEDLINE, Google scholar, and Cochrane controlled trials register databases from inception till May 2021. Risk of cognitive deficit was the primary endpoint, while secondary endpoints were length of stay (LOS) in intensive care unit/hospital. Impact of individual studies and cumulative evidence reliability were evaluated with sensitivity analyses and trial sequential analysis, respectively.
Results:
Six RCTs involving 963 patients published from 1999 to 2019 were included. In early postoperative period (i.e., 2 weeks), the use of intravenous lidocaine (overall incidence = 14.8%) was associated with a lower risk of cognitive deficit compared to that with placebo (overall incidence = 33.1%) (relative risk = 0.49, 95% confidence interval: 0.32–0.75). However, sensitivity analysis and trial sequential analysis signified insufficient evidence to arrive at a firm conclusion. In the late postoperative period (i.e., 6–10 weeks), perioperative intravenous lidocaine (overall incidence = 37.9%) did not reduce the risk of cognitive deficit (relative risk = 0.99, 95% confidence interval: 0.84) compared to the placebo (overall incidence = 38.6%). Intravenous lidocaine was associated with a shortened LOS in intensive care unit/hospital with weak evidence.
Conclusion:
Our results indicated a prophylactic effect of intravenous lidocaine against cognitive deficit only at the early postoperative period despite insufficient evidence. Further large-scale studies are warranted to assess its use for the prevention of cognitive deficit and enhancement of recovery (e.g., LOS).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.